TGTX / TG Therapeutics, Inc. null

SecurityTGTX / TG Therapeutics, Inc.
Form TypeCORRESP
File Date2018-07-18
 
 
 
TG Therapeutics, Inc.
  
July 18, 2018
 
Securities and Exchange Commission
Department of Corporation Finance
Washington, D.C. 20549
Attn: Ms. Christine Westbrook
 
 
Via:
EDGAR Submission
 
 
Re:
TG Therapeutics, Inc.
Registration Statement on Form S-3
Filed July 9, 2018
File No. 333-226097
 
Ladies and Gentlemen:
 
TG Therapeutics, Inc. (the “Company”), hereby requests that the effective date for the Registration Statement referred to above be accelerated so that it will be declared effective at 9:00 a.m. (ET) on July 23, 2018 or as soon as practicable thereafter, pursuant to Rule 461 of the Securities Act of 1933, as amended.
 
The Company acknowledges that (i) should the Commission or the staff of the Commission, acting pursuant to delegated authority, declare the filing effective, such declaration does not foreclose the Commission from taking any action with respect to the filing; (ii) the action of the Commission or the staff of the Commission, acting pursuant to delegated authority, in declaring the filingeffective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and (iii) the Company may not assert the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
 
Please contact Mark F. McElreath of Alston & Bird LLP with any questions or comments at 212-210-9595. Thank you for your assistance with this filing.
 
 
TG THERAPEUTICS, INC.
 
 
 
 
By:
/s/ Sean Power
 
 
 
Sean Power
 
 
Chief Financial Officer
 
cc:
Mark F. McElreath